Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Terminated Phase 3 Interventional Results available

Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions

NCT01986946
View directory record Official record
Conditions
Lumbar Spine Fusion, Pain, Back Pain
Interventions
Epidural Catheter - Dilaudid, Dilaudid
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 24, 2026, 4:17 PM EDT
Completed No phase listed Observational

CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function

NCT00610896
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated Phase 3 Interventional Results available

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04093362
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
Interventions
Futibatinib, Cisplatin, Gemcitabine
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • Louisville, Kentucky • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 24, 2026, 4:17 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Saline in Posterior Spinal Fusion

NCT06822374
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis;Congenital
Interventions
Normosol-R, buffered 2% hypertonic saline
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

NCT03689582
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 24, 2026, 4:17 PM EDT
Completed No phase listed Observational

Study of OP-1 Putty in Uninstrumented Posterolateral Fusions

NCT00678353
View directory record Official record
Conditions
Degenerative Lumbar Spondylolisthesis
Interventions
Not listed
Lead sponsor
Olympus Biotech Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Santa Monica, California • Stanford, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated No phase listed Observational

Interbody Systems: Post Market Clinical Follow-up Study

NCT04911257
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Cervical or Lumbar Spinal fusion
Device
Lead sponsor
K2M, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Shreveport, Louisiana • Cleveland, Ohio • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Post-Approval Clinical Trial of the PCM® Cervical Disc

NCT01905930
View directory record Official record
Conditions
Radiculopathy, Myelopathy
Interventions
PCM Cervical Disc, Anterior Cervical Discectomy and Fusion (ACDF)
Device
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 65 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Beverly Hills, California • Greenwood Village, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 24, 2026, 4:17 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

IO Vancomycin Spine

NCT06748144
View directory record Official record
Conditions
Lumbar Fusion Surgery
Interventions
Intraosseous Vancomycin, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated No phase listed Observational

Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

NCT01293981
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
PureGen Osteoprogenitor Cell Allograft
Biological
Lead sponsor
Alphatec Spine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Beverly Hills, California • Middleton, Connecticut • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Results available

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT03358719
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Anemia
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Nivolumab, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NCT05222165
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811
View directory record Official record
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

NCT00041587
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Denver, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated No phase listed Observational

Assessment and Tracking of Long-term Alefacept Safety

NCT00454701
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 24, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Not applicable Interventional

CONDUIT vs. PEEK Cages

NCT06904898
View directory record Official record
Conditions
Lumbar Degenerative Disease
Interventions
Cougar LS/Syncage ALIF or CONDUIT LLIF/ALIF cage
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Withdrawn Not applicable Interventional

Assessment of Low Level Laser Therapy for Late Postoperative Pain After Lumbar Fusion Surgery

NCT00422045
View directory record Official record
Conditions
Surgery
Interventions
Low Level Laser Therapy
Device
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075
View directory record Official record
Conditions
Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Ocular Melanoma, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

NCT00722839
View directory record Official record
Conditions
Nonneoplastic Condition
Interventions
PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 24, 2026, 4:17 PM EDT
Completed Not applicable Interventional

Coflex PS3 Actual Conditions for Use Study

NCT02555280
View directory record Official record
Conditions
Spinal Stenosis Lumbar
Interventions
coflex® Interlaminar Technology, Decompression
Device · Procedure
Lead sponsor
Companion Spine, LLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • San Luis Obispo, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 24, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Alefacept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 24, 2026, 4:17 PM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery

NCT00798902
View directory record Official record
Conditions
Degenerative Disc Disease, Spondylolisthesis
Interventions
Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules, Iliac crest autograft
Device · Other
Lead sponsor
BioSurface Engineering Technologies, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Durango, Colorado • Washington D.C., District of Columbia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 24, 2026, 4:17 PM EDT